Cogent Biosciences to present pivotal data on bezuclastinib and JAK2 V617F at EHA Congress, June 2026.
Quiver AI Summary
Cogent Biosciences, Inc. announced the acceptance of two presentations related to its Advanced Systemic Mastocytosis (AdvSM) program at the upcoming European Hematology Association (EHA) Congress in Stockholm from June 11-14, 2026. Notably, an oral presentation will feature pivotal data from the APEX trial on bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation involved in systemic mastocytosis. Dr. Daniel DeAngelo will present the study's efficacy and safety results on June 13. Additionally, a poster presentation will showcase preclinical findings from Cogent's new JAK2 V617F program, which will be presented by Mark J Chicarelli. Cogent focuses on precision therapies for genetically defined diseases and has several targeted treatments in development.
Potential Positives
- Pivotal data from the APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation at a major medical conference, highlighting the company's leading position in this therapeutic area.
- This marks Cogent's third oral presentation of pivotal data with bezuclastinib, underscoring ongoing confidence in its development and potential impact on patient care.
- Acceptance of preclinical data from the selective, potent JAK2 V617F program for poster presentation demonstrates the company's commitment to innovation and expansion of its therapeutic pipeline.
Potential Negatives
- Acceptance of pivotal data for oral presentation may imply that previous results need further validation, raising concerns about the robustness of the company’s clinical data.
- Details on the delivery of key clinical trial results, including the specific efficacy and safety data, are not included in the press release, leaving potential gaps in stakeholder understanding of the drug's value.
- The press release does not disclose any commercial partnerships or funding specifics, which may raise questions about the future financial stability and support for ongoing research and development efforts.
FAQ
What is the APEX trial focused on?
The APEX trial investigates the efficacy and safety of bezuclastinib in patients with advanced systemic mastocytosis.
When will the APEX trial results be presented?
Results from the APEX trial will be presented orally on June 13, 2026, at the EHA Congress in Stockholm.
Who is presenting the research on bezuclastinib?
Daniel DeAngelo, M.D., Ph.D., from the Dana-Farber Cancer Institute, will present the research on bezuclastinib.
What is the focus of the JAK2 V617F program presentation?
The JAK2 V617F program presentation will focus on the preclinical characterization of a novel selective inhibitor, CGT1145.
How can I learn more about Cogent Biosciences?
You can visit Cogent Biosciences' website at www.cogentbio.com for more information on their research and therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COGT Insider Trading Activity
$COGT insiders have traded $COGT stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $COGT stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT has made 0 purchases and 2 sales selling 10,500,000 shares for an estimated $370,020,000.
- JOHN EDWARD ROBINSON (Chief Scientific Officer) sold 90,000 shares for an estimated $3,486,600
- JESSICA SACHS (Chief Medical Officer) sold 82,642 shares for an estimated $3,198,245
- JOHN L. GREEN (Chief Financial Officer) sold 77,000 shares for an estimated $2,978,360
- EVAN KEARNS (Chief Legal Officer) sold 65,000 shares for an estimated $2,515,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$COGT Hedge Fund Activity
We have seen 180 institutional investors add shares of $COGT stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 7,592,241 shares (+inf%) to their portfolio in Q4 2025, for an estimated $269,676,400
- COMMODORE CAPITAL LP removed 5,053,155 shares (-69.7%) from their portfolio in Q4 2025, for an estimated $179,488,065
- VANGUARD GROUP INC added 3,756,664 shares (+48.4%) to their portfolio in Q4 2025, for an estimated $133,436,705
- PARADIGM BIOCAPITAL ADVISORS LP removed 3,156,398 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $112,115,256
- BLACKROCK, INC. added 2,605,056 shares (+25.1%) to their portfolio in Q4 2025, for an estimated $92,531,589
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,474,346 shares (+2758.0%) to their portfolio in Q4 2025, for an estimated $87,888,769
- WELLINGTON MANAGEMENT GROUP LLP added 2,305,437 shares (+566.6%) to their portfolio in Q4 2025, for an estimated $81,889,122
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$COGT Analyst Ratings
Wall Street analysts have issued reports on $COGT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 01/21/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/06/2026
- JP Morgan issued a "Overweight" rating on 12/19/2025
To track analyst ratings and price targets for $COGT, check out Quiver Quantitative's $COGT forecast page.
$COGT Price Targets
Multiple analysts have issued price targets for $COGT recently. We have seen 5 analysts offer price targets for $COGT in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $55.0 on 05/06/2026
- David Nierengarten from Wedbush set a target price of $55.0 on 03/17/2026
- Faisal Khurshid from Jefferies set a target price of $55.0 on 03/16/2026
- Christopher Raymond from Piper Sandler set a target price of $52.0 on 02/18/2026
- Anupam Rama from JP Morgan set a target price of $67.0 on 12/19/2025
Full Release
-
Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings
- Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation
WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations from the company’s Advanced Systemic Mastocytosis (AdvSM) program, including an oral presentation highlighting the results of the APEX trial, as well as a poster presentation from its emerging JAK2 V617F program at the European Hematology Association (EHA) Congress being held in Stockholm, Sweden, June 11-14, 2026.
Details of the presentations are as follows:
Bezuclastinib
Oral Presentation
Abstract Title:
Efficacy and Safety of Bezuclastinib in Patients With Advanced Systemic Mastocytosis: Primary Results From the Apex Study
Presenter:
Daniel DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School
Session Date and Time:
June 13, 2026 – 17:15 – 18:30 CEST (11:15 AM ET – 12:30 PM ET)
Oral Session:
S438 Myeloproliferative Neoplasms – Clinical
Session Room:
A2-3 Hall
Poster Presentation
Abstract Title:
The Effect of Bezuclastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results from the Pivotal Apex Trial
Poster #:
PF885
Presenter:
Tracy George, M.D., President and Chief Scientific Officer at ARUP Laboratories, Professor of Pathology at the University of Utah School of Medicine
Session Date and Time:
June 12, 2026 – 18:45-19:45 CEST (12:45pm - 1:45pm ET)
JAK2 V617F
Poster Presentation
Abstract Title:
Preclinical characterization of CGT1145 a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Poster #:
PF853
Presenter:
Mark J Chicarelli, Senior Director Medicinal Chemistry, Cogent Biosciences
Session Date and Time:
June 12, 2026 – 18:45-19:45 CEST (12:45pm - 1:45pm ET)
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media:
X
(formerly known as Twitter) and
LinkedIn
. Information that may be important to investors will be routinely posted on our website and
X
.
Contact:
Christi Waarich
Senior Director, Investor Relations
[email protected]
617-830-1653
